[{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 69, "title": "Executive Chairman", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 7190594, "exercisedValue": 0, "unexercisedValue": 47864680}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 4616880, "exercisedValue": 0, "unexercisedValue": 15390147}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 55, "title": "Executive VP & CFO", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 3132761, "exercisedValue": 0, "unexercisedValue": 5589906}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 60, "title": "Executive VP & COO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3510428, "exercisedValue": 5248500, "unexercisedValue": 23376292}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 54, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 4315363, "exercisedValue": 2125307, "unexercisedValue": 9617938}, {"maxAge": 1, "name": "Dr. Roopal  Thakkar M.D.", "age": 51, "title": "Executive VP of Research and Development & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Perry C. Siatis", "age": 48, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay  Narayan", "title": "Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 57, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1121841, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 4, "compensationRisk": 2, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 171.52, "open": 171.794, "dayLow": 170.66, "dayHigh": 176.8, "regularMarketPreviousClose": 171.52, "regularMarketOpen": 171.794, "regularMarketDayLow": 170.66, "regularMarketDayHigh": 176.8, "dividendRate": 6.56, "dividendYield": 0.0374, "exDividendDate": 1736899200, "payoutRatio": 2.1359, "fiveYearAvgDividendYield": 4.13, "beta": 0.613, "trailingPE": 61.391613, "forwardPE": 14.421036, "volume": 17496344, "regularMarketVolume": 17496344, "averageVolume": 6234395, "averageVolume10days": 7479040, "averageDailyVolume10Day": 7479040, "bid": 175.74, "ask": 175.58, "bidSize": 900, "askSize": 800, "marketCap": 310274424832, "fiftyTwoWeekLow": 153.58, "fiftyTwoWeekHigh": 207.32, "priceToSalesTrailing12Months": 5.5872083, "fiftyDayAverage": 182.7612, "twoHundredDayAverage": 178.83275, "trailingAnnualDividendRate": 6.2, "trailingAnnualDividendYield": 0.036147386, "currency": "USD", "enterpriseValue": 374351495168, "profitMargins": 0.09222999, "floatShares": 1763994813, "sharesOutstanding": 1767139968, "sharesShort": 19324304, "sharesShortPriorMonth": 18125235, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0109, "heldPercentInsiders": 0.00096000003, "heldPercentInstitutions": 0.73432, "shortRatio": 2.46, "shortPercentOfFloat": 0.0109, "impliedSharesOutstanding": 1767139968, "bookValue": 3.413, "priceToBook": 51.444477, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.122, "netIncomeToCommon": 5080999936, "trailingEps": 2.86, "forwardEps": 12.13, "enterpriseToRevenue": 6.741, "enterpriseToEbitda": 14.606, "52WeekChange": 0.13555813, "SandP52WeekChange": 0.2421279, "lastDividendValue": 1.55, "lastDividendDate": 1728950400, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "messageBoardId": "finmb_141885706", "gmtOffSetMilliseconds": -18000000, "currentPrice": 175.58, "targetHighPrice": 240.0, "targetLowPrice": 165.0, "targetMeanPrice": 202.54214, "targetMedianPrice": 205.0, "recommendationMean": 1.89655, "recommendationKey": "buy", "numberOfAnalystOpinions": 28, "totalCash": 7285000192, "totalCashPerShare": 4.122, "ebitda": 25629999104, "totalDebt": 71323000832, "quickRatio": 0.436, "currentRatio": 0.645, "totalRevenue": 55532998656, "debtToEquity": 1174.815, "revenuePerShare": 31.397, "returnOnAssets": 0.077199996, "returnOnEquity": 0.56407, "freeCashflow": 17738999808, "operatingCashflow": 16510999552, "earningsGrowth": -0.123, "revenueGrowth": 0.038, "grossMargins": 0.70335, "ebitdaMargins": 0.46153, "operatingMargins": 0.28928, "financialCurrency": "USD", "trailingPegRatio": 0.4194, "__fetch_time": "2024-12-21"}]